Evidence map›Paper›PMID 34483024›Full record

ArticleVaccine2023

Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies.

Arend Voorman, Kathleen O'Reilly, Hil Lyons, Ajay Kumar Goel, Kebba Touray, Samuel Okiror

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Arend VoormanThe Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109, United States. Electronic address: arend.voorman@gatesfoundation.org.
Kathleen O'ReillyThe London School of Hygiene and Tropical Medicine, Keppel St, Bloomsbury, London WC1E 7HT United Kingdom.
Hil LyonsThe Institute for Disease Modelling, 500 5th Ave N, Seattle, WA 98109, United States.
Ajay Kumar GoelThe World Health Organization, Avenue Appia 20, 1202 Genève, Switzerland.
Kebba TourayThe World Health Organization Regional Office for Africa, Cité du Djoué, P.O.Box 06, Brazzaville, Republic of Congo.
Samuel OkirorThe World Health Organization Regional Office for Africa, Cité du Djoué, P.O.Box 06, Brazzaville, Republic of Congo.
World Health Organization Regional Office for Africa · CGGates Foundation · USInstitute for Disease Modeling · USUniversity of London · GBWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundCirculating vaccine-derived poliovirus outbreaks are spreading more widely than anticipated, which has generated a crisis for the global polio eradication initiative. Effectively responding with vaccination activities requires a rapid risk assessment. This assessment is made difficult by the low case-to-infection ratio of type 2 poliovirus, variable transmissibility, changing population immunity, surveillance delays, and limited vaccine supply from the global stockpile. The geographical extent of responses have been highly variable between countries.

methodsWe develop a statistical spatio-temporal model of short-term, district-level poliovirus spread that incorporates known risk factors, including historical wild poliovirus transmission risk, routine immunization coverage, population immunity, and exposure to the outbreak virus.

resultsWe find that proximity to recent cVDPV2 cases is the strongest risk factor for spread of an outbreak, and find significant associations between population immunity, historical risk, routine immunization, and environmental surveillance (p < 0.05). We examine the fit of the model to type 2 vaccine derived poliovirus spread since 2016 and find that our model predicts the location of cVDPV2 cases well (AUC = 0.96). We demonstrate use of the model to estimate appropriate scope of outbreak response activities to current outbreaks.

conclusionAs type 2 immunity continues to decline following the cessation of tOPV in 2016, outbreak responses to new cVDPV2 detections will need to be faster and larger in scope. We provide a framework that can be used to support decisions on the appropriate size of a vaccination response when new detections are identified. While the model does not account for all relevant local factors that must be considered in the overall vaccination response, it enables a quantitative basis for outbreak response size.

Indexed as

PoliomyelitisPoliovirusDisease OutbreaksHumansPoliovirus Vaccine, OralVaccinationPoliovirus Vaccine, Oral

Identifiers

PMID34483024
PMCPMC10109086
OpenAlexW3197156770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.